Page 1 of 2

We value your insights

We hope you enjoyed the recent event, Advancing NMIBC diagnosis and treatment: Cutting-Edge Technologies and Clinical Approaches, on AIS Medical Network. We are constantly working to bring you the best insights and content, so we would love to hear your thoughts. Please answer a few questions about the session's highlights to help us shape the future of medical education together.

1. Which of the following companies sponsored the episode you just have watched?

Storz

Cook

Olympus

Boston Scientific

Richard Wolf

Dornier

Coloplast

Stryker

2. To what extent did this episode contribute to increasing your knowledge in your field of practice? (Please use a scale of 1 to 5 where 1 = did not increase my knowledge at all; and 5 = increased my knowledge considerably)

3. When considering acquiring a new imaging system/tower, what is the most important factor you take into consideration?

The image quality of imaging system/tower

Additional imaging features (NBI/PDD/4K)

Training program offered by the manufacturer

Clinical evidence related to technology

The cost of the imaging system/tower

Quality of service and after sales support

Reference from other surgeons, colleagues and peers

4. After this episode, do you wish to learn more about using imaging system/tower for NMIBC detection and treatment?

Yes

5. For future sessions focusing on bladder cancer management, which topics would you be most interested in?

Techniques for flexible cystoscopy and learning-curve.

Techniques for TURBT and en-block TUR

Interpretation and assessment of cystoscopic imaging findings

Clinical approaches to challenging cases

Treatment strategies, including chemotherapy and intravesical therapy

Use of enhanced imaging technologies (e.g., NBI, PDD) in diagnosis and treatment

Case-based discussions and panel reviews

6. Would you like to be contacted by the company supporting this event (Olympus) to receive further information?

Yes

Note: An AIS Medical Network representative will contact you first to confirm your data-sharing preferences